The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics.
Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution), formerly known as Brimochol PF, achieves effect after around 30 minutes and lasts for up to 10 hours, according to Tenpoint. It is the first dual-agent eye drop approved for the treatment of presbyopia and the fourth topical treatment approved overall, following Vuity (pilocarpine HCl ophthalmic solution 1.25%, AbbVie), Qlosi